Nanotechnology RSS feeds

ENJOY THE BENEFITS

Simply Register to GAIN ACCESS to lots more info

USER LOGIN


copyright-Nanovip 2008

tags in Event type

NANO FACTS

...Nanometres...
nanotechnology companies | nanotechnology info Human hair 80,000 nm wide
nanotechnology companies | nanotechnology info Red blood cell 7,000 nm wide
nanotechnology companies | nanotechnology info Water molecule 0.3 nm wide
nanotechnology companies | nanotechnology info Sheet Paper 100,000 nm wide

PRODUCTS

LATEST MEMBERS

  • divsgr8
  • santucci
  • tobiass
  • Marilena Bartic
  • likeweather
  • rkd5310

WHO'S ONLINE

There are currently 0 users and 18 guests online.

  Valid XHTML 1.0 Transitional

Button for your site

Quantum Pharmaceuticals Drug Discovery Software


   




KEEP UPDATED WITH NANOVIP CONTENT - USE OUR RSS FEEDS HERE
Visit this link

Phone :
+7 495 156-15-61

Fax :
+7 495 150-83-32

The proprietary technology includes the latest achievements in the fields of chemistry, physics and mathematics. It demonstrates outstanding speed and accuracy of affinity calculations due to fast quantum calculations, which take into account full flexibility of molecules, solvation effects, and entropy contribution. This provides unprecedented possibilities for drug discovery.

Quantum Pharmaceuticals’ technology has made it possible to create Q-Lead Libraries, a revolutionary product for the pharmaceutical industry. These libraries will dramatically alter the drug discovery process by reducing or eliminating the time involved in this stage of R&D.

Quantum’s proprietary computer-based technology is succesfuly used in collaborative and in-house Quantum Pharmaceuticals’ projects to develop drug candidates for dozens of diseases including AIDS, TB, Alzheimer’s disease, COPD and others.



» | Edit this entry
                                                                                                                                                                                                                                                                                          
Back to previous page Go to the top of this page